Zim Laboratories (ZIMLAB) | Stock Overview & Key Data
Zim Laboratories Performance Comparison
Stock Range
Today's Range
Low: ₹77.11
High: ₹80.00
on August 8, 2025
52 Week Range
Low: ₹77.01
High: ₹128.90
on August 7, 2025
All-Time High: ₹127.00 on July 18, 2025
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR3.9B
EPS
2.50
P/E Ratio (TTM)
31.92
Forward P/E
N/A
P/B Ratio
1.54
PEG Ratio
-1.09
Div. Yield
N/A
ROE
4.96%
Beta
0.407
Debt to Equity
46.70
Financial Highlights
Profitability
Gross Margin
55.62%
Operating Margin
9.43%
Profit Margin
3.21%
Returns and Earnings
Return on Assets (TTM)
3.34%
Return on Equity (TTM)
4.96%
EBITDA
INR495.1M
Net Income (TTM)
INR121.7M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR77.81
Quarterly Revenue Growth (YoY)
-7.70%
Quarterly Earnings Growth (YoY)
-39.60%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Zim Laboratories ZIMLAB | 3.89B Small-cap | -28.02% | -32.10% | -24.14% | -24.14% | -24.14% | -22.64% | -22.64% | -22.64% |
| Sun Pharmaceutical SUNPHARMA | 3.92T Large-cap | -2.63% | -5.12% | -10.20% | -8.38% | -16.03% | -8.55% | 73.73% | 198.65% |
| Divi's Laboratories DIVISLAB | 1.63T Large-cap | -7.03% | -14.75% | -0.77% | -0.41% | -2.61% | 22.45% | 58.73% | 91.42% |
| Sun Pharma Advanced SPARC | 48.23B Small-cap | -4.83% | -8.86% | 0.02% | -8.70% | -28.94% | -34.79% | -34.46% | -20.13% |
| Aarti Drugs AARTIDRUGS | 44.83B Small-cap | 0.47% | 3.52% | 17.71% | 21.40% | 7.96% | -1.73% | 18.09% | -4.28% |
| Sequent Scientific SEQUENT | 44.76B Small-cap | -0.34% | -9.41% | 8.30% | 7.32% | -9.00% | 22.29% | 57.12% | 26.68% |
Ownership & Short Interest
Insider Ownership
69.99%
Institutional Ownership
0.00%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
311K
Average 90-Day Volume
276K
Zim Laboratories Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Zim Laboratories would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ZIMLAB's 52-week high and low?
- In the last 52 weeks, Zim Laboratories reached a high of ₹128.90 (on N/A) and a low of ₹77.01 (on August 7, 2025).
- What is the market cap and P/E ratio for ZIMLAB?
- Curious about Zim Laboratories's size and valuation? Its market capitalization stands at 3.89B. When it comes to valuation, the P/E ratio (trailing twelve months) is 31.92, and the forward P/E (looking ahead) is N/A.
- Does ZIMLAB pay dividends? If so, what's the yield?
- As for dividends, Zim Laboratories isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Zim Laboratories's main competitors or similar companies to consider before investing?
When looking at Zim Laboratories, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.92T Healthcare Drug Manufacturers - Specialty & Generic -8.55% 73.73% Divi's Laboratories
DIVISLAB1.63T Healthcare Drug Manufacturers - Specialty & Generic 22.45% 58.73% Sun Pharma Advanced
SPARC48.23B Healthcare Drug Manufacturers - Specialty & Generic -34.79% -34.46% Aarti Drugs
AARTIDRUGS44.83B Healthcare Drug Manufacturers - Specialty & Generic -1.73% 18.09% Sequent Scientific
SEQUENT44.76B Healthcare Drug Manufacturers - Specialty & Generic 22.29% 57.12% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Zim Laboratories Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Zim Laboratories's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 4.96%, the Debt to Equity ratio from the most recent quarter is 46.70, and its Gross Profit Margin stands at 55.62%.
- What is the recent revenue and earnings growth for ZIMLAB?
- Looking at Zim Laboratories's growth, its revenue over the trailing twelve months (TTM) was INR4B. Compared to the same quarter last year (YoY), quarterly revenue grew by -7.70%, and quarterly earnings saw a YoY growth of -39.60%.
- How much of ZIMLAB stock is held by insiders and institutions?
- Wondering who owns Zim Laboratories stock? Company insiders (like executives and directors) hold about 69.99% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.